Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment.
Borgmann
A
A
Department of Pediatric Oncology/Hematology, Virchow-Klinikum, Medizinische Fakultät, Humboldt Universität Berlin, Kliniken und Polikliniken, Germany.
von Stackelberg
A
A
Baumgarten
E
E
Uchanska-Ziegler
B
B
Ziegler
A
A
Wittig
B
B
Henze
G
G
D000293:Adolescent; D016026:Bone Marrow Transplantation; D019496:Cancer Vaccines; D002648:Child; D002985:Clinical Protocols; D018076:DNA, Complementary / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D015235:HLA-B Antigens / Q000235:genetics*; D059908:HLA-B13 Antigen; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D010865:Pilot Projects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000628:therapy*; D012008:Recurrence; D014162:Transfection / Q000379:methods; D014611:Vaccination
D019496:Cancer Vaccines; D018076:DNA, Complementary; D015235:HLA-B Antigens; D059908:HLA-B13 Antigen; D007376:Interleukin-2